Semaglutide in Treatment of Obesity

NCT06604624 · Completed

Last updated 2026-05-28

This clinical trial tested the medication semaglutide in adults with obesity to see how it affects body weight over 44 weeks of treatment.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 462 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-09 · est. completion 2025-09

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06604624 ↗

Description as written by the study sponsor.

This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.

Treatments tested

HD1916 Drug

HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
semaglutide Drug

semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week

Main thing measured	Relative percentage change in body weight from baseline at 44 weeks of treatment
Sponsor	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions studied	Weight Management
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06604624 ↗